Sugi Predict

Sugi Predict / Compounds / SCHEMBL1817058

SCHEMBL1817058

SCHEMBL1817058

C[C@](N)(Cc1ccc(F)cc1)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BLM P54132 2/20 0.71
▸ HPGD P15428 2/20 0.60
▸ KDM4E B2RXH2 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ USP2 O75604 1/20 0.60
▸ EGFR P00533 1/20 0.60
▸ CYP1A2 P05177 1/20 0.60
▸ FYN P06241 1/20 0.60
▸ POLB P06746 1/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ GAA P10253 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ ALOX15 P16050 1/20 0.60
▸ APEX1 P27695 1/20 0.60
▸ ADRA1A P35348 1/20 0.60
▸ PTGS2 P35354 1/20 0.60
▸ MTOR P42345 1/20 0.60
▸ RECQL P46063 1/20 0.60
▸ CASP6 P55212 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1817057 1.00 BLM (0.71) BLMHPGDKDM4EALDH1A1MEN1
SCHEMBL9079628 1.00 BLM (0.71) BLMHPGDKDM4EALDH1A1MEN1
SCHEMBL15218062 0.83 BLM (0.73) BLMHPGDKDM4EALDH1A1MEN1
Metyrosine SCHEMBL50398 0.83 BLM (1.00) BLMHPGDKDM4EALDH1A1MEN1
Hydrochloric Acid SCHEMBL11335295 0.83 BLM (0.73) BLMHPGDKDM4EALDH1A1MEN1
SCHEMBL6717499 0.83 BLM (0.73) BLMHPGDKDM4EALDH1A1MEN1
Racemetyrosine SCHEMBL61871 0.83 BLM (1.00) BLMHPGDKDM4EALDH1A1MEN1
SCHEMBL6717498 0.83 BLM (0.73) BLMHPGDKDM4EALDH1A1MEN1
Hydrochloric Acid SCHEMBL11335298 0.83 BLM (0.73) BLMHPGDKDM4EALDH1A1MEN1
Metyrosine SCHEMBL162280 0.83 BLM (1.00) BLMHPGDKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 — — US claimed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 — — US claimed
EP-4127157-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-02-08 — — EP claimed
WO-2022072560-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2022-04-07 — — WO claimed
WO-2021194908-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2021-09-30 — — WO claimed
US-20160022636-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2016-01-28 — — US claimed
EP-2968240-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP claimed
US-20140336216-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-11-13 — — US claimed
WO-2014152917-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO claimed
EP-4613761-A9 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES Janssen Biotech, Inc. (US) 2025-10-22 — — EP disclosed
EP-4613761-A2 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES Janssen Biotech, Inc. (US) 2025-09-10 — — EP disclosed
EP-4090670-B1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES JANSSEN BIOTECH INC (US) 2025-06-04 — — EP disclosed
US-20250154198-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR ZEALAND PHARMA A/S (DK) 2025-05-15 — — US disclosed
EP-4440592-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2024-10-09 — — EP disclosed
US-20080227774-A1 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2008-09-18 — — US disclosed
US-20080227774-A1 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2008-09-18 — — US disclosed
WO-2008022015-A2 RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-02-21 — — WO disclosed
US-20070293497-A1 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease MERCK SHARP & DOHME LLC 2007-12-20 — — US disclosed
US-20070265255-A1 SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS GEORGETOWN UNIVERSITY 2007-11-15 — — US disclosed
US-20070110813-A1 Polycation-polyanion complexes, compositions and methods of use thereof AERIS THERAPEUTICS, INC. (US) 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293497-A1 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease BACE1, BACE2, PSEN2 BLM 4446/4885HPGD 878/4885KDM4E 1359/4885
US-20080227774-A1 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS CYP3A5, IPO5, IDO1 BLM 3642/4885HPGD 1169/4885KDM4E 1369/4885
US-20070265255-A1 SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS ADH5, ADH1C, ADH1A BLM 1685/4885HPGD 916/4885KDM4E 1744/4885
US-20250154198-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR IL23R, IL1RN, IL33 BLM 4785/4885HPGD 1288/4885KDM4E 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.